According to the research report, the global clinical trial biorepository and archiving solutions market size is expected to touch USD 9.3 Billion by 2032, from USD 4.1 Billion in 2022, growing with a significant CAGR of 5.84% from 2023 to 2032.
Key Takeaways:
- North American region generated more than 49% of the revenue share in 2022.
- By Product, the clinical segment generated more than 64% of the revenue share in 2022.
- By Phase, the phase III segment captured more than 53% of revenue share in 2022.
- By Phase, the Phase II segment is expected to expand at the fastest CAGR between 2023 and 2032.
- By Services, the biorepository services segment generated more than 67% of revenue share in 2022.
- By Services, the archiving solutions segment is expected to grow at the fastest growth rate between 2023 and 2032.
The clinical trial biorepository and
archiving solutions report offers a comprehensive study of the current state
expected at the major drivers, market strategies, and key vendors’ growth. The
report presents energetic visions to conclude and study the market size, market
hopes, and competitive surroundings. The research also focuses on the important
achievements of the market, research & development, and regional growth of
the leading competitors operating in the market. The current trends of the
global clinical trial biorepository and archiving solutions in conjunction with
the geographical landscape of this vertical have also been included in this
report.
The report offers intricate dynamics about
different aspects of the global clinical trial biorepository and archiving
solutions market, which aids companies operating in the market in making
strategic development decisions. The study also elaborates on significant
changes that are highly anticipated to configure growth of the global clinical
trial biorepository and archiving solutions during the forecast period. It also
includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2749
| Report Coverage | Details |
| Market Size in 2023 | USD 4.45 Billion |
| Market Size by 2032 | USD 9.3 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.84% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Phase, and By Services |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation
of the global clinical trial biorepository and archiving solutions market,
along with key information and a competition outlook. The report mentions
company profiles of players that are currently dominating the global clinical
trial biorepository and archiving solutions market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Thermo Fisher Scientific Inc.
- Azenta U.S.
- Charles River Laboratories
- LabCorp Drug Development
- Precision for Medicine Inc.
- Medpace
- Labconnect
- Q2 Solutions
Market Segmentation
By Product
- Preclinical Products
- Clinical Products
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Services
- Biorepository Services
- Archiving Services
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global clinical trial biorepository and archiving
solutions report is based on detailed primary as well as secondary research.
With the help of in-depth insights of the market-affiliated information that is
obtained and legitimated by market-admissible resources, analysts have offered
riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market association
publications, and company websites to obtain the necessary understanding of the
global clinical trial biorepository and archiving solutions market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Clinical Trial Biorepository and Archiving Solutions Market
5.1. COVID-19 Landscape: Clinical Trial Biorepository and Archiving Solutions Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Clinical Trial Biorepository and Archiving Solutions Market, By Product
8.1. Clinical Trial Biorepository and Archiving Solutions Market, by Product, 2023-2032
8.1.1 Preclinical Products
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Clinical Products
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Clinical Trial Biorepository and Archiving Solutions Market, By Phase
9.1. Clinical Trial Biorepository and Archiving Solutions Market, by Phase, 2023-2032
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Clinical Trial Biorepository and Archiving Solutions Market, By Services
10.1. Clinical Trial Biorepository and Archiving Solutions Market, by Services, 2023-2032
10.1.1. Biorepository Services
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Archiving Services
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Clinical Trial Biorepository and Archiving Solutions Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.2. Market Revenue and Forecast, by Phase (2020-2032)
11.1.3. Market Revenue and Forecast, by Services (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Services (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.2. Market Revenue and Forecast, by Phase (2020-2032)
11.2.3. Market Revenue and Forecast, by Services (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Services (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Phase (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Services (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Phase (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Services (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.2. Market Revenue and Forecast, by Phase (2020-2032)
11.3.3. Market Revenue and Forecast, by Services (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Services (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Phase (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Services (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Phase (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Services (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Services (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Phase (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Services (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Phase (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Services (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.5.3. Market Revenue and Forecast, by Services (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Phase (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Services (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Phase (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Services (2020-2032)
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Azenta U.S.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Charles River Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. LabCorp Drug Development
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Precision for Medicine Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Medpace
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Labconnect
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Q2 Solutions
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments